Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. Prostrakan launched Sancuso in the U.S. in ...
2009 OCT 19 ... mg/kg) > roflumilast (1.6) > cilomilast (6.4) > EPPA-1 (24.3). The low and high emetogenic activities of EPPA-1 and rolipram, respectively, detected in the pica model were ...
2009 JUN 22 ... ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery. The NDA is supported by positive data from ...
2009 AUG 4 ... NK1 receptors. After 3 days, shrews were challenged intraperitoneally with the emetogenic NK1 agonist GR73632 at different doses, and vomiting and scratching behaviors were ...
2009 NOV 16 ... palonosetron is effective in preventing CINV in patients receiving moderately or highly emetogenic chemotherapy", he added. "We have previously shown that a single dose of palonosetron ...
2009 JUL 6 ... antiemetic agents (e.g. olanzapine, gabapentin, cannabinoids) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone ...
2009 JUL 13 ... of GRN given at 1 mg in Japanese cancer patients. Patients with cancer receiving highly emetogenic chemotherapy were enrolled in this single-blind randomized controlled study." ...
2009 NOV 16 ... combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy,' is newly published data in Annals of Oncology. "This is a randomized, ...
2009 AUG 3 ... or vitamin B6 alone in controlling emesis of 142 patients undergoing a highly emetogenic chemotherapy regimen between March 1, 2006, and June 30, 2008," scientists in Harbin, ...
2009 NOV 16 ... phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy,' are ...
2009 JUL 27 ... or vomiting or require rescue therapy following administration of certain types of emetogenic chemotherapy", said Richard Gralla, Vice President Cancer Services, North Shore ...
2009 JUL 6 ... or vomiting or require rescue therapy following administration of certain types of emetogenic chemotherapy", said Richard Gralla, Vice President Cancer Services, North Shore ...
2009 JUN 22 ... (CINV) in patients with aggressive non-Hodgkin's lymphomas who undergo moderately emetogenic chemotherapy. New data presented today at the EHA (European Haematology Association) ...
2009 JUN 22 ... ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.
The ODFS, a new oral formulation ...
2009 MAY 4 ... "Patients with breast cancer often receive emetogenic anthracycline-based chemotherapy as part of their treatment. Chemotherapy-induced nausea ...
2009 AUG 31 ... Treatments with a 5-HT3 Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy. Anticancer Research, 2009;29(5):1721-1725). For additional ...
2009 JUL 27 ... and vomiting (CINV) remains a clinical management problem after treatment with highly emetogenic chemotherapy (HEC). We therefore designed and carried out a multicentre, randomised, ...
2009 JUN 22 ... of acute antineoplastic-induced nausea and vomiting in adults receiving highly emetogenic therapy. The lack of an oral liquid dosage form is one barrier to its use in children," ...
2009 JUL 27 ... in the combined regimen recommended for emesis prevention in patients undergoing highly emetogenic chemotherapy (HEC). Last week, MASCC (Multinational Association for Supportive Care in ...
